As such, the in situ activity of sEH has been used as a proxy for pathogenicity and/or inflammation and inhibition of sEH activity has been associated with improved disease outcome, especially in pathologies involving the vascular endothelium in their etiology.95, 96, 97 Despite being effective in diabetic retinopathy,94 sEH inhibition does not modify insulin sensitivity89 suggesting that CYP-sEH pathway acts on different levels in T2DM.98 This evidence concerns the gene EPHX2 and type 2 diabetes mellitus.